ClinicalTrials.gg
Active, not recruitingNCT05297890Updated May 19, 2026

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

A Phase 2 interventional study of Lorlatinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer, sponsored by CStone Pharmaceuticals. Active, not recruiting at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by CStone Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 27
70 · median 45
Started
2022
the only one that year
Phase 2
16 of 27
6 open now
Primary completion
2023-12
later than 1 of 15 live
Registered
15th of 27
by date
Lead sponsor
1 of 27
CStone Pharmaceuticals

Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 16 in phase 2, reaches primary completion later than 1 of the 15 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lorlatinib

lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China

03

Conditions studied

  • Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with or cytologically confirmed diagnosis of locally advanced or ROS1 gene arrangement positive NSCLC.
  • Subject should have radiological disease progression while on treatment with crizotinib as the only prior ROS1 inhibitor.
  • Participants must have been treated with platinum-based doublet chemotherapy for locally advanced/metastatic disease for at least 1 cycle and must have radiological disease progression on or after that. Participants who do not tolerate platinum-based doublet chemotherapy may be included provided they have been treated for at least 1 cycle.
  • Prior treatment with small molecules or cytotoxic agents must have completed ≥5 half-lives prior to initiating study treatment; Prior treatment with antibodies must have completed at least 3 weeks prior to initiating study treatment.
  • All Subjects must have at least 1 measurable target lesion (intracranial or extracranial) according to v1.1.
  • performance status (ECOG PS) 0, 1, or 2.
  • Age ≥18 years.
  • Subjects must have adequate organ function as assessed in the laboratory tests.
  • Acute effects of prior anti-cancer treatment resolved to baseline severity or to National Cancer Institute (NCI) (CTCAE 5.0) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.
  • Serum or urine pregnancy test (for females of ) negative at screening.
  • Evidence of a personally signed and dated document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.

Exclusion criteria

Exclusion Criteria:

  • More than 1 prior chemotherapy regimen prior to enrollment in the locally advanced/ setting.
  • Subject's cancer has a known primary driver alteration other than ROS1 gene rearrangement.
  • Major surgery within 4 weeks prior to the first dose.
  • Radiation therapy within 2 weeks prior to the first dose. Palliative radiation must have been completed at least 48 hours prior to the first dose. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to the first dose. Whole brain irradiation must have completed at least 4 weeks prior to the first dose.
  • Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to the first dose.
  • Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.
  • Known prior or suspected severe to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.
  • Severe acute or chronic infections.
  • cardiovascular disease (both arterial and venous) and non-vascular cardiac conditions (active or within 3 months prior to the first dose).
  • Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to the first dose.
  • History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
  • Evidence of active within the last 3 years prior to the first dose.
  • Concurrent use of any of the prohibited food or drugs required in protocol within 12 days prior to the first dose of administration of lorlatinib.
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, would make the subject inappropriate for entry into this study.
  • Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
  • Pregnant female subjects; breastfeeding female subjects.
  • Any use of traditional Chinese medicines or herbal preparations with anti-tumor indications within 7 days before the first dose of investigational product.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Lorlatinib

    Drug:Lorlatinib 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle

    Drug: Lorlatinib

Interventions

  • Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per Independent Central Radiology (ICR) assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

Secondary outcomes

  1. Duration of response (DoR) as assessed by RECIST v1.1 per ICR assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  2. ORR assessed by RECIST version 1.1 per investigator assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  3. DoR assessed by RECIST version 1.1 per investigator assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  4. Disease control rate (DCR) at 12 and 24 week as assessed by RECIST v1.1 per ICR assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  5. Time to tumor response (TTR) as assessed by RECIST v1.1 per ICR assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  6. Progression-free survival (PFS) as assessed by RECIST v1.1 per ICR assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  7. Intracranial Objective Response (IC-OR) as assessed by RECIST v1.1 per ICR assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  8. Duration of intracranial response (IC-DoR) as assessed by RECIST v1.1 per ICR assessment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  9. Overall survival (OS)

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  10. To evaluate the safety and tolerability of lorlatinib treatment

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  11. Lorlatinib concentration will be used for population PK analysis

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

  12. patient-reported outcomes (PROs) as assessed by EORTC QLQ-C30 and EORTC QLQ-LC13 (self-assessment questionnaires)

    Time frame: From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months

07

Study locations

31 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2023, 18 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 18 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2022
First posted
Mar 28, 2022
StartActual
May 27, 2022
Primary completionActual
Dec 26, 2023
CompletionEst.
May 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05297890
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 28, 2022
Start date
May 27, 2022
Primary completion
Dec 26, 2023
Completion
May 2027 (estimated)
Last update
May 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion